Novo Nordisk has announced that the U.S. Food and Drug Administration (FDA) has approved the Biologics License Application for REBINYN® (Coagulation Factor IX (Recombinant), GlycoPEGylated) for the treatment of adults and children with hemophilia B. REBINYN® is the brand name for nonacog beta pegol, N9-GP. REBINYN® is indicated for on-demand treatment and control of bleeding episodes, […]
The post FDA approves new Hemophilia treatment appeared first on CenterWatch News Online.
Powered by WPeMatico